What We're Reading: Page 263
Industry reads hand-picked by our editors
Jun 01, 2018
May 31, 2018
-
Financial Times
Drugmakers struggle to find immunotherapy combinations for cancer
-
The Atlantic
Why Egypt is at the forefront of hepatitis C treatment
-
The Washington Post
This mock pandemic killed 150 million people. Next time it might not be a drill.
-
Forbes
Inside the gene factory
May 30, 2018
-
The Wall Street Journal
Are big clinical trials relevant? Researchers disagree
-
Reuters
India’s drug regulator expects to finalize new clinical trial rules in two months
-
The Atlantic
Genetic intelligence tests are next to worthless
-
Massive
'Orphan drugs' are ascendant. What will that mean for people with rare diseases?
May 29, 2018
-
The New York Times
Origins of an epidemic: Purdue Pharma knew its opioids were widely abused
-
The Boston Globe
For Boston’s brainy biotech crowd, there’s nothing like an early morning run
-
Bloomberg
China’s health-care stocks are scorching hot
-
Medical Marketing & Media
How drugmakers are facing the entrance of consumer giants into healthcare
May 25, 2018
-
Bloomberg
America is losing the race to develop the sunscreens of the future
-
Xconomy
Immunotherapy biotech Kiromic considers San Antonio move for cash
-
Regulatory Focus
Kickback allegation settlements pile up for pharmaceutical companies
-
Austin Business Journal
Law powerhouse Reed Smith plants roots in Austin, takes aim at biotech business
May 24, 2018
May 23, 2018
-
Bloomberg
Gene therapies that could transform diseases get easier FDA path
-
Chemical & Engineering News
$50 million more for CARB-X will help biotech companies fight antibiotic resistance
-
Los Angeles Times
New 'unified theory' of childhood leukemia raises possibility of preventing the disease
-
Associated Press
Many cancer patients juggle care along with financial pain
Previous
